1. Ault P, Jones K. Understanding iron overload: screening, monitoring, andcaring for patients with transfusion-dependent anemias. Clin J Oncol Nurs.2009;13(5):511-517.
2. Andrews NC. Disorders of iron metabolism. N Engl J Med. 1999;341(26):1986-1995.
3. Cappellini MD, Taher A. Deferasirox (Exjade®) for the treatment of ironoverload. Acta Haematol. 2009;122(2-3):165-173.
4. VanOrden HE, Hagemann TM. Deferasirox—an oral agent for chronic ironoverload. Ann Pharmacother. 2006;40(6):1110-1117.
5. Cappellini MD, Cohen A, Eleftheriou A, et al, eds. Guidelines for the ClinicalManagement of Thalassaemia. 2nd revised ed. Nicosia, Cyprus: ThalassaemiaInternational Federation; 2008.
6. Fung EB, Harmatz P, Milet M, et al. Morbidity and mortality in chronicallytransfused subjects with thalassemia and sickle cell disease: A report fromthe multi-center study of iron overload. Am J Hematol. 2007;72(4):255-265.
7. National Library of Medicine. Genetics Home Reference. Beta thalassemia.Available at: AccessedJanuary 4, 2010.
8. Kwiatkowski JL. Oral iron chelators. Pediatr Clin N Am. 2008;55(2):461-482.
9. Centers for Disease Control and Prevention. Thalassemia. Available at: Accessed January 19,2010.
10. Haywood C, Beach MC, Lanzkrons S, et al. A systemic review of barriersand interventions to improve appropriate use of therapies for SCD.J Natl Med Assoc. 2009;101(10):1022-1033.
11. National Heart, Lung and Blood Institute. The Management of Sickle CellDisease. 4th Ed. Bethesda, Md: National Institutes of Health; 2002. NIHpublication 02-2217.
12. Galanello R, Piga A, Cappellini MD, et al. Effect of food, type of food, andtime of food intake on deferasirox bioavailability: recommendations foran optimal deferasirox administration regimen. J Clin Pharmacol.2008;48(4):428-435.
13. National Comprehensive Cancer Network (NCCN). NCCN Clinical PracticeGuidelines in Oncology. Myelodysplastic Syndromes. V2.2010.
14. Tefferi A, Vardiman JW. Myelodysplastic Syndromes. N Engl J Med.2009;361(19):1872-1885.
15. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplasticsyndromes and chronic myeloproliferative disorders in the United States,2001-2004, using data from the NAA CCR and SEER programs. Blood.2008;112(1):45-52.
16. Cappellini MD, Taher A. Long-term experience with deferasirox (ICL670),a once-daily oral iron chelator, in the treatment of transfusional ironoverload. Expert Opin Pharmacother. 2008;9(13):2391-2402.
17. Jabbour E, Garcia-Manero G, Taher A, Kantarjian HM. Managing iron overloadin patients with myelodysplastic syndromes with oral deferasirox therapy.The Oncologist. 2009;14(5):489-496.
18. International Association of Sickle Cell Nurses & Physician Assistants(IASCNAPA). Nursing practice guidelines: care of the patient with sicklecell disease and iron overload. 2008. Accessed December 17, 2009.
19. Screening and monitoring for iron overload. January 4, 2010.
20. National Library of Medicine. Ferritin. Available at: Accessed January 4, 2010.
21. Exjade [package insert]. East Hanover, NJ: Novartis PharmaceuticalsCorporation; 2010.
22. Mir MA, Logue GL. Transfusion-induced iron overload. AccessedDecember 17, 2008.
23. Desferal [package insert]. East Hanover, NJ: Novartis PharmaceuticalsCorporation; 2007.
24. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670),a once-daily oral iron chelator, in patients with beta-thalassemia. Blood.2006;107(9):3455-3462.
25. Galanello R, Piga A, Forni GL, et al. Phase II clinical evaluation of deferasirox,a once-daily oral chelating agent, in pediatric patients with beta-thalassemiamajor. Haematologica. 2006;91(10):1343-1351.
26. Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox(Exjade®, ICL670), a once-daily, orally-administered iron chelator, incomparison to deferoxamine in thalassemia patients with transfusionaliron overload. Haematologica. 2006;91(7):873-880.
27. Porter J, Galanello R, Saglio G, et al. Relative response of patients withmyelodysplastic syndromes and other transfusion-dependent anaemiasto deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol.2008;80(2):168-176.
28. Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison ofdeferasirox versus deferoxamine for the treatment of transfusional ironoverload in sickle cell disease. Br J Haematol. 2007;136(3):501-508.
29. Taher A, Cappellini MD. Update on the use of deferasirox in the managementof iron overload. Ther Clin Risk Manag. 2009;5:857-868.
30. Data on file. Novartis Pharmaceuticals Corporation. 2009.
31. Cappellini M, El-Beshlawy A, Kattamis A, et al. Efficacy and safety ofdeferasirox (Exjade®) in patients with transfusion-dependent anemias:1-year results from the large, prospective, multicenter EPIC study. Blood.2008;112(11): abstract 3875.
32. Gattermann N. Efficacy and safety of deferasirox (Exjade®) during 1 yearof treatment in transfusion-dependent patients with myelodysplasticsyndromes: results from the EPIC trial. Blood. 2008;112(11): abstract 633.
33. Taher A, El-Beshlawy A, Elalfy MS, et al. Efficacy and safety of deferasirox,an oral iron chelator, in heavily iron-overloaded patients with betathalassaemia:the ESCALATOR study. Eur J Haematol. 2009;82(6):458-465.
34. Taher A, El-Beshlawy A, Elalfy M, et al. Deferasirox significantly reducesiron burden in heavily iron-overloaded patients with beta-thalassaemia:2.7 year results from the ESCALATOR study. Haematologica. 2009;94(Suppl 2): abstract 209.
35. Pennell D, Porter JB, Cappellini MD, et al. Efficacy and safety of deferasirox(Exjade®) in reducing cardiac iron in patients with β-thalassemia major,results from the cardiac substudy of the EPIC trial. Blood. 2008;112(11):abstract 3873.
36. Wood JC, Thompson AA , Paley C, et al. Deferasirox (Exjade®) monotherapysignificantly reduces cardiac iron burden in chronically transfusedβ-thalassemia patients: an MRI T2* study. Blood. 2008;112(11): abstract3882.
37. Reyal Y, Chowdhury O, Kirk P, et al. Improvement in cardiac T2* withdeferasirox in transfused patients with cardiac iron overload. Haematologica.2008;93(Suppl 1): abstract 846.
38. Garbowski M, Eleftheriou P, Pennell D, et al. Impact of compliance, ferritinand LIC on long-term trends in myocardial T2* with deferasirox. Blood.2008;112(11): abstract 116.
39. Pennell D, Sutcharitchan P, El-Beshlawy A, et al. Efficacy and safety ofdeferasirox (Exjade®) in preventing cardiac iron overload in β-thalassemiapatients with normal baseline cardiac iron: results from the cardiac substudyof the EPIC trial. Blood. 2008;112(11): abstract 3874.
40. Pathare A, Taher A, Daar S. Deferasirox (Exjade®) significantly improvescardiac T2* in heavily iron-overloaded patients with β-thalassemia major.Ann Hematol. Published online 02 Oct 2009.
41. Schmid M, Cappellini MD, Porter JB, et al. Safety of deferasirox (Exjade®)in myelodysplastic syndromes (MDS) and non-MDS patients withtransfusional iron overload: a pooled analysis focusing on renal function.Blood. 2009;114(22): abstract 1768.
42. Gattermann N, Leismann O, Schlag R, et al. Deferasirox (Exjade) treatmentof chelation-naive and pre-chelated MDS patients with transfusionaliron-overload in the medical practice: Results from the observationalstudies Extend and Exjange. Blood. 2009;114(22): abstract 3805.
43. List AF, Baer MR, Steensma D, et al. Two year analysis of deferasiroxtreatment efficacy and safety in myelodysplastic syndrome patients inthe US03 study. Blood. 2009;114(22): abstract 3829.
44. Cappellini MD, Bejaoui M, Agaoglu L, et al. Prospective evaluationof patient-reported outcomes during treatment with deferasirox ordeferoxamine for iron overload in patients with β-thalassemia. Clin Ther.2007;29(5):909-917.
45. Cioffi G, Bates B, Butler C, et al. Exploring barriers and facilitators totreatment adherence among people with thalassemia and theircaregivers. 2009. Accessed February 18, 2010.
46. Vichinsky E, Pakbaz Z, Onyekwere O, et al. Patient-reported outcomes ofdeferasirox (Exjade, ICL670) versus deferoxamine in sickle cell diseasepatients with transfusional hemosiderosis. Substudy of a randomizedopen-label phase II trial. Acta Haematol. 2008;119(3):133-141.
47. Pilo F, Di Tucci AA , Dessi L, Angelucci E. Management of transfusional ironoverload: focus on deferasirox. Clin Med Ther. 2009;1:735-745.
48. Vichinsky E. Clinical application of deferasirox: practical patient management.Am J Hematol. 2008;83(5):398-402.
49. Iron Overload Nurse Ambassador Program (IONA). Management of irontoxicity. Accessed January 4, 2010.
50. Cianciulli P. Treatment of iron overload in thalassemia. Pediatr EndocrinolRev. 2008;6(Suppl 1):208-213.
51. Raphael JL, Bernhardt MB, Mahoney DH, et al. Oral iron chelation and thetreatment of iron overload in a pediatric hematology center. Blood Cancer.2009;52(5):616-620.
52. Hellström-Lindberg E. Efficacy of erythropoietin in the myelodysplasticsyndromes. An analysis of 205 patients in 17 studies. Br J Haematol. 1995;89(1):67-71.
53. Hellström–Lindberg E, Gulbrandsen N, Lindberg G, et al. A validateddecision model for treating the anaemia of myelodysplastic syndromeswith erythropoietin + granulocyte colony-stimulating factor: significanteffects on quality of life. Br J Haematol. 2003;120(6):1037-1046.